公司資料
Vera Therapeutics 股價、新聞與催化劑
- 股票代碼:
- VERA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
31.63 USD (0.00%)
收盤價
最後更新: 2026年8月17日
2.24B USD
市值
股價為何變動
As of Aug 17, 2026, VERA was little changed and closed at $31.63. No new same-company headline was identified in the current news window.
公司概覽
Kidney-Disease Biologics
Vera Therapeutics develops therapies for immune-mediated kidney diseases. Its lead program targets B-cell survival signals implicated in abnormal antibody production.
Atacicept
Atacicept is a recombinant TACI fusion protein that binds BAFF and APRIL. It is under Priority Review for accelerated approval in adults with IgA nephropathy.
Commercial Transition
Vera is preparing to move from clinical development into a commercial-stage model centered on atacicept, subject to FDA approval.
未來催化劑
- FDA PDUFA target action date for atacicept on July 7, 2026.
- Potential U.S. launch of atacicept around mid-2026, subject to approval.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。